The effect of S-adenosylmethionine on self-mutilation in a patient with Lesch–Nyhan disease
M Lauber, B Plecko, M Pfiffner, JM Nuoffer… - JIMD Reports, Volume …, 2017 - Springer
JIMD Reports, Volume 32, 2017•Springer
Abstract Background: Lesch–Nyhan disease (LND) is an X-chromosomal disorder of purine
metabolism characterized by hyperuricemia, dystonia, and self-mutilation, leading to an
extremely high burden of disease in affected patients and families. Although allopurinol
therapy can control hyperuricemia, it has no effect on self-mutilation and neurological
symptoms. Single reports describe a beneficial effect of S-adenosylmethionine (SAM) on the
neurological symptoms, which motivated us to evaluate this alternative treatment. Methods …
metabolism characterized by hyperuricemia, dystonia, and self-mutilation, leading to an
extremely high burden of disease in affected patients and families. Although allopurinol
therapy can control hyperuricemia, it has no effect on self-mutilation and neurological
symptoms. Single reports describe a beneficial effect of S-adenosylmethionine (SAM) on the
neurological symptoms, which motivated us to evaluate this alternative treatment. Methods …
Abstract
Background: Lesch–Nyhan disease (LND) is an X-chromosomal disorder of purine metabolism characterized by hyperuricemia, dystonia, and self-mutilation, leading to an extremely high burden of disease in affected patients and families. Although allopurinol therapy can control hyperuricemia, it has no effect on self-mutilation and neurological symptoms. Single reports describe a beneficial effect of S-adenosylmethionine (SAM) on the neurological symptoms, which motivated us to evaluate this alternative treatment.
Methods: We performed a double-blind placebo-controlled trial to analyze the effects of SAM on self-mutilation attempts in a male patient affected by LND. The trial lasted for 282 days and comprised three alternating verum and placebo periods of 50 days each. The mother of the patient recorded attempts of self-mutilation during the entire trial.
Results: While verum and placebo were both well tolerated, a total of 1,762 events of self-mutilation were recorded, of which 1,281 events were in the placebo period and 481 in the verum period. The daily mean of events was 8.6 with placebo and 4.5 with SAM corresponding to a 50 % decrease in self-mutilation events under SAM treatment (p < 0.05).
Conclusion: The results of this double-blind placebo-controlled single-case trial suggest that SAM can have a beneficial effect on self-mutilation in patients with LND, possibly by replenishing the purine pool in affected brain cells.
Springer